SCHEMBL73418

SCHEMBL73418

CCOP(=O)(Cc1ccc(C(=O)OC)cc1)OCC

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 1/20 0.53
MAPT P10636 3/20 0.50
CYP4A11 Q02928 2/20 0.49
CYP4F2 P78329 1/20 0.47
CA1 P00915 3/20 0.46
CA2 P00918 3/20 0.46
TDP1 Q9NUW8 2/20 0.46
CA12 O43570 1/20 0.46
CA7 P43166 1/20 0.46
CA9 Q16790 1/20 0.46
CA14 Q9ULX7 1/20 0.46
HDAC1 Q13547 1/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
NPC1 O15118 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
RAB9A P51151 1/20 0.46
ALDH1A1 P00352 2/20 0.44
HPGD P15428 2/20 0.44
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL915111 0.95 LOXL2 (0.49) LOXL2MAPTCYP4A11CYP4F2CA1
SCHEMBL510962 0.87 MEN1 (0.56) MAPTCA1CA2TDP1CA12
SCHEMBL915436 0.87 LOXL2 (0.53) LOXL2MAPTCYP4A11CYP4F2CA1
SCHEMBL2208162 0.86 LOXL2 (0.51) LOXL2MAPTCYP4A11CYP4F2CA1
SCHEMBL1758645 0.85 LOXL2 (0.58) LOXL2MAPTCYP4A11CYP4F2CA1
SCHEMBL10726455 0.84 CYP4A11 (0.54) LOXL2MAPTCYP4A11CYP4F2CA1
SCHEMBL915654 0.84 KDM4E (0.46) LOXL2MAPTCYP4A11CYP4F2CA1
SCHEMBL7770750 0.84 PLK1 (0.59) CA1TDP1CA12CA9HDAC1
SCHEMBL8671670 0.83 HDAC1 (0.45) MAPTHDAC1MEN1KMT2AALDH1A1
SCHEMBL454324 0.83 ALDH1A1 (0.53) MAPTTDP1HDAC1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0813516-B1 PROCESS FOR THE PREPARATION OF STILBENEDICARBOXYLATE ESTERS EASTMAN CHEM CO (US) 1999-12-01 EP claimed
US-5473098-A Process for the preparation of stilbenedicarboxylate esters EASTMAN CHEMICAL COMPANY (US) 1995-12-05 US claimed
EP-4719384-A2 COMPOUNDS WITH ANTIFUNGAL PROPERTIES Trustees of Dartmouth College (US) 2026-04-08 EP disclosed
WO-2025262297-A1 PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 DARK BLUE THERAPEUTICS LTD (GB) 2025-12-26 WO disclosed
US-12479797-B2 Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors Jubilant Epicore LLC (US) 2025-11-25 US disclosed
EP-3455204-B1 CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS Jubilant Epicore LLC (US) 2025-10-29 EP disclosed
US-20250298333-A1 POLYESTER RESIN COMPOSITION, ELECTROSTATIC CHARGE IMAGE DEVELOPING TONER, DEVELOPER, AND IMAGE FORMING METHOD Konica Minolta, Inc. (JP) 2025-09-25 US disclosed
US-12281119-B2 Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist BEIGENE, LTD. (KY) 2025-04-22 US disclosed
WO-2024249290-A2 COMPOUNDS WITH ANTIFUNGAL PROPERTIES TRUSTEES OF DARTMOUTH COLLEGE (US) 2024-12-05 WO disclosed
EP-3921320-B1 IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST BEIGENE LTD (KY) 2024-03-06 EP disclosed
US-20230250106-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-08-10 US disclosed
US-5523457-A Retinoid-like compounds BRISTOL-MYERS SQUIBB COMPANY (US) 1996-06-04 US disclosed
US-5473098-A Process for the preparation of stilbenedicarboxylate esters EASTMAN CHEMICAL COMPANY (US) 1995-12-05 US disclosed
EP-0661259-A1 Substituted (5,6)-dihydronaphthalenyl compounds having retinoid-like activity BRISTOL-MYERS SQUIBB COMPANY (US) 1995-07-05 EP disclosed
EP-0661261-A1 Phenyl or phenylalkyl substituted naphtalene derivatives having retinoid-like activity as well as anti-tumor activities BRISTOL-MYERS SQUIBB COMPANY (US) 1995-07-05 EP disclosed
US-4532241-A Inhibiting neoplastic growth SRI INTERNATIONAL (US) 1985-07-30 US disclosed
US-4460591-A ANTITUMOR AGENTS SRI INTERNATIONAL (US) 1984-07-17 US disclosed
US-4366189-A WHITENERS CIBA-GEIGY CORPORATION (US) 1982-12-28 US disclosed
US-4233440-A OPTICAL BRIGHTENERS BAYER AKTIENGESELLSCHAFT (DE) 1980-11-11 US disclosed
US-4167628-A OPTICAL BRIGHTENERS CIBA-GEIGY CORPORATION (US) 1979-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250106-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 LOXL2 978/4885MAPT 3027/4885CYP4A11 3911/4885
US-12479797-B2 Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors HDAC1, HDAC11, HDAC2 LOXL2 839/4885MAPT 33/4885CYP4A11 654/4885
US-12281119-B2 Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist TLR7, TLR1, TLR3 LOXL2 3347/4885MAPT 4191/4885CYP4A11 1108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.